Isabelle Riviere, PhDDirector, Michael G. Harris Cell Therapy and Cell Engineering Facility, Molecular Pharmacology at Memorial Sloan Kettering Cancer Center
Dr. Rivière received her Ph.D. in Cellular and Molecular Biology from the University of Paris. She initiated her graduate studies at the Institut Curie in Paris and completed her thesis in the laboratory of Dr. Mulligan at the Whitehead Institute in Cambridge, MA. During this time, she developed novel retroviral vectors to investigate the in vivo long-term expression of transgenes in hematopoietic cells using MFG/SFG-based retroviral vectors that are widely used in clinical studies for the treatment of genetic and acquired disorders. She subsequently worked as a post-doctoral fellow in the laboratory of Dr. D. Littman at New York University, NY. Her studies focused on the regulation of cytokines produce by T helper lymphocytes in vivo. Dr. Rivière joined the faculty of Memorial Sloan-Kettering Cancer Center in 1999. She is currently the Director of the Michael G. Harris Cell Therapy and Cell Engineering laboratory where she investigates the genetic modification of hematopoietic cells to increase or retarget the immune response against tumors and to treat genetic disorders. Her laboratory has developed cell manufacturing processes under GMP conditions for several Phase I/II clinical trials in the academic setting. She actively participates in the National Cell Manufacturing Consortium Workshop that led to the establishment of the “Technology Roadmap to 2025 for Achieving Large Scale, Cost effective, Reproducible Manufacturing of High-Quality Cells”. She is a member of the Board of Directors of the American Society of Gene and Cell Therapy (ASGCT), the Alliance for Regenerative Medicine (ARM) and the Center for Commercialization of Cancer Immunotherapy C3i (Canada). She is also an active member of the International Society of Cell Therapy (ISCT) and the International Society of Stem Cell Research (ISSCR).